BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/25/2018 3:44:36 AM | Browse: 1053 | Download: 1630
 |
Received |
|
2018-07-16 04:51 |
|
Peer-Review Started |
|
2018-07-16 06:40 |
|
First Decision by Editorial Office Director |
|
2018-07-24 16:13 |
|
Return for Revision |
|
2018-07-31 06:38 |
|
Revised |
|
2018-08-02 11:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-08-20 06:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-08-24 09:09 |
|
Articles in Press |
|
2018-08-24 09:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-09-20 08:00 |
|
Publish the Manuscript Online |
|
2018-09-25 03:44 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ioanna Aggeletopoulou, Stelios F Assimakopoulos, Christos Konstantakis and Christos Triantos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Christos Triantos, PhD, Assistant Professor, Chief Doctor, Senior Scientist, Department of Gastroenterology, University Hospital of Patras, D. Stamatopoulou 4, Patras 26504, Greece. chtriantos@upatras.gr |
| Key Words |
Crohn’s disease; Interleukin 12; Interleukin 23; Monoclonal antibodies; Ustekinumab; Biological agents; Interleukin 12/interleukin 23 blockade |
| Core Tip |
The therapeutic management of Crohn’s disease patients not responding to treatment with anti-tumor necrosis factor agents remains a clinical challenge. Recently, there has been increased evidence regarding the development of new drugs with alternative mechanisms of action. Interleukin (IL)-12 and IL-23 are important cytokines which are involved in the adaptive immune responses and their common pathway has been found to play a determinant role in the induction of inflammation. Clinical trials have assessed the therapeutic effect of an IL-12/IL-23 inhibitor (ustekinumab), demonstrating rapid clinical effect with a safety profile. Further studies are needed to elucidate its potential role as first-line therapy in Crohn’s disease. |
| Publish Date |
2018-09-25 03:44 |
| Citation |
Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol 2018; 24(36): 4093-4103 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i36/4093.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i36.4093 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
